BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.
- Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place virtually on April 8, 2024 at 8:00a.m EDT. A live webcast of the fireside chat will be available through this link, and also available on the Investors + Media section of the company's website www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.
- Management will also participate in the Piper Sandler Spring Biopharma Symposium, taking place in Boston, MA on April 16-17, 2024.
About PraxisPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit¯www.praxismedicines.com¯and follow us on¯Facebook,¯LinkedIn¯and¯Twitter/X.¯
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact:Dan FerryLife Science AdvisorsDaniel@lifesciadvisors.com617-430-7576